Clinical TrialKetamineKetaminePlaceboCompleted

CAP-Ketamine for Antidepressant Resistant PTSD

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.

Target Enrollment
Not specified
Study Type
Phase II interventional
Design
Randomized

Study Arms & Interventions

Standard Dose

experimental

Ketamine 0.5 mg/kg administered via 8 intravenous infusions, twice weekly.

Interventions

  • Ketamine0.5 mg/kg
    via IVtwice weekly8 doses total

    8 infusions total

Low Dose

experimental

Ketamine 0.2 mg/kg administered via 8 intravenous infusions, twice weekly.

Interventions

  • Ketamine0.2 mg/kg
    via IVtwice weekly8 doses total

    8 infusions total

Placebo

placebo

Intravenous placebo (normal saline) administered twice weekly.

Interventions

  • Placebo
    via IVtwice weekly8 doses total

    normal saline

Primary Results(1 publication)

Participants

N = 158Mean age: 42–45.2 across armsG. et al. 2022

PCL-5

Score at Timepoint

Standard DoseDay 28·G. et al. 2022

Adverse Events (from all publications)

Arm / GroupnAny TEAESevereSeriousDiscont.
Standard Doseexperimental5146(90.2%)
Low Doseexperimental5346(86.8%)
Placeboplacebo5445(83.3%)

* Based on Table S1: # Subjects Reporting 46. Total AEs reported was 138.

* Based on Table S1: # Subjects Reporting 46. Total AEs reported was 154.

* Based on Table S1: # Subjects Reporting 45. Total AEs reported was 110.

Study Details

  • Status
    Completed
  • Phase
    Phase II
  • Type
    interventional
  • Design
    Randomized
  • Timeline
    Start: 2016-04-18
    End: 2020-07-01
  • Compounds

Related Publications

Your Library